Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivatuzumab mertansine in advanced head and neck cancer
NCT02254018Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2002
- Primary completion
- Feb 2005
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of bivatuzumab mertansine in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Boehringer Ingelheim. Primary endpoint: Maximum tolerated dose. Started Sep 2002; status: completed.
02
Drugs
bivatuzumab mertansine
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02254018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254018.